HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies

Summary

The study will consist of a dose-escalation and dose-expansion component to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D), and to evaluate the preliminary antitumor activity of HX044. HX044 is an investigational drug that has not yet been approved by the Food and Drug Administration (FDA) or any other regulatory authorities for commercial purposes. This is the first study in which HX044 will be given to humans. The study drug has been tested in animals and was found to be well-tolerated with minimal side effects.

Timeline

Start

2024-12-30

Primary completion

2025-10-31

Completion

2027-10-31

Drugs

Indications